An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 3, 2014, Pages 623-630

  Murakami, H ^a   Kurata, T ^b   Onozawa, Y ^a   Watanabe, J ^a   Ono, A ^a   Takahashi, T ^a   Yamamoto, N ^a   Fujisaka, Y ^b   Kiyota, H ^b   Hayashi, H ^b   Tanaka, K ^b   Nakagawa, K ^b   Kuroda, S ^c  

^a SHIZUOKA CANCER CENTER   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c Division of Gastrointestinal Oncology Shizuoka Cancer Center ^*  (Japan)

Author keywords

Japanese patients; Ombrabulin; Pharmacokinetic; Phase I; Vascular disrupting agent

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; OMBRABULIN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANGINA PECTORIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTERIAL THROMBOEMBOLISM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CAUCASIAN; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; CONJUNCTIVAL HYPEREMIA; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HOT FLUSH; HUMAN; HYPERSENSITIVITY; HYPERTENSION; INJECTION SITE PHLEBITIS; JAPANESE; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; SINUS BRADYCARDIA; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; YOUNG ADULT;

ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SERINE;

EID: 84896039635     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2388-x     Document Type: Article

References (27)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70 (Pubitemid 30046295)
2. Denekamp J (1999) The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur J Clin Invest 29:733-736
3. Delmonte A, Sessa S (2009) AVE8062: a new combretastatin derivative vascular disrupting agent. Expert Opin Investig Drugs 18:1541-1548
4. Kanthou C, Tozer GM (2002) The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99:2060-2069 (Pubitemid 34525489)
5. Hori K, Saito S (2003) Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 89:1334-1344 (Pubitemid 37363426)
6. Seed L, Slaughter DP, Limarzi LR (1940) Effect of colchicine on human carcinoma. Surgery 7:696-709
7. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ (1993) Vinca alkaloids: anti-vascular effects in a murine tumor. Eur J Cancer 29A:1320-1324 (Pubitemid 23169906)
8. Chaplin DJ, Pettit GR, Parkins CS, Hill SA (1996) Antivascular approaches to solid tumor therapy: evaluation of tubulin binding agents. Br J Cancer 74(Suppl. 27):S86-S88 (Pubitemid 26237935)
9. Marshall JL, Hawkins MJ (1995) The clinical experience with antiangiogenic agents. Breast Cancer Res Treat 36:253-261
10. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garia-Kendall D (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A4. Experientia 45:205-211
11. Woods JA, Hadfield JA, Pettit GR, Fox BW, McGown AT (1995) The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 71(4):705-711
12. Dark GD, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834 (Pubitemid 27209705)
13. Chaplin DJ, Pettit GR, Hill SA (1999) Anti-vascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19:189-195 (Pubitemid 29168237)
14. Nihei Y, Suzuki M, Okano A et al (1999) Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 90:1387-1395 (Pubitemid 30032079)
15. Nihei Y, Suga Y, Morinaga Y et al (1999) A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res 90:1016-1025 (Pubitemid 29500443)
16. Lavisse S, Lejeune P, Rouffiac V et al (2008) Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 43:100-111
17. Tozer GM, Prise VE, Wilson J et al (1999) Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59:1626-1634 (Pubitemid 29160136)
18. Hori K, Saito S, Nihei Y, Suzuki M, Sato Y (1999) Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 90:1026-1038 (Pubitemid 29500444)
19. Sessa C Lorusso P, Tolcher AW et al (2013) A phase I safety, pharmacokinetic and pharmacodynamic study of AVE8062, a novel vascular disrupting agent, in patients with advanced solid tumors. Clin Camcer Res 19:4832-4842
20. Jouannot E, Carrez C, Lassau N et al (2007) Demonstration in animal and human of AVE8062-induced tumor blood flow shutdown using dynamic contrast enhanced-ultrasonography (DCEUS). 98th AACR annual meeting, 2007, April 14-18, Abstract No LB-328
21. Tresca P, Tosi D, van Doorn L et al (2010) Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors. J Clin Oncol 28(15s):3023
22. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
23. Sessa C, Lorusso P, Tolcher AW et al (2005) A pharmacokinetic and DCE-MRI-dynamic Phase I study of the antivascular combretastatin analogue AVE8062A administered every 3 weeks [Abstract]. Proc Am Assoc Cancer Res 46, Abstract No 5827
24. Subbiah IM, Lenihan DJ, Tsimberidou AM (2011) Cardiovascular toxicity profiles of vascular-disrupting agents. Oncol 16:1120-1130
25. Bertolini F, Shaked Y, Mancuso P, Kerbel RS (2006) The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6:835-845 (Pubitemid 44629895)
26. Massard C, Borget I, Le Deley MC et al (2012) Prognostic value of circulating VEGFR2 + bone marrow-derived progenitor cells in patients with advanced cancer. Eur J Cancer 48:1354-1362
27. Taylor M, Billiot F, Marty V et al (2012) Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. Cancer Discov 2:434-449